Compass Therapeutics Investor Presentation Deck

Percent tumor decline Phase 2 CTX-009 Data Responses achieved across multiple BTC subclasses. Data as of November 9, 2022 Patient Number 0 -10 -20 -30 -40 -50 -60 1 -1 2 -7 3 -7 4 5 6 7 8 9 10 11 -12 COMPASS THERAPEUTICS -9 Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Gallbladder cancer Ampullary cancer -12 -12 -17 -17 -19 11 -20 12 -25 13 -33 2 patients were not evaluable (one missing post baseline scan; one had a scan outside of protocol window) 14 -33 15 -37 16 CONFIRMED PARTIAL RESPONSE -38 17 -41 18 -44 19 ORR = 37.5% CBR = 91.5% -44 20 -48 21 -52 22 -57 17

View entire presentation